SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 10,355.29 |
Enterprise Value ($M) | 11,384.99 |
Book Value ($M) | 1,221.07 |
Book Value / Share | 12.78 |
Price / Book | 8.48 |
NCAV ($M) | 306.51 |
NCAV / Share | 3.21 |
Price / NCAV | 33.78 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.05 |
Return on Assets (ROA) | 0.04 |
Return on Equity (ROE) | 0.14 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.03 |
Current Ratio | 3.84 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 2,685.37 |
Assets | 3,599.93 |
Liabilities | 2,378.86 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Capital International Investors | |||
13G/A | Janus Henderson Group Plc | 4.60 | -18.47 | |
13G/A | BlackRock, Inc. | 10.70 | 61.55 | |
13G/A | Vanguard Group Inc | 9.42 | 9.75 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
122,168 | 543,029 | 22.50 | |
272,084 | 766,491 | 35.50 | |
183,138 | 559,081 | 32.76 | |
303,523 | 1,031,655 | 29.42 | |
(click for more detail) |
Similar Companies | |
---|---|
SLRN – Acelyrin, Inc. | SNDX – Syndax Pharmaceuticals, Inc. |
SPRO – Spero Therapeutics, Inc. | SRRK – Scholar Rock Holding Corporation |
STOK – Stoke Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io